Key Points
- Director Jan Malcolm sold 50 UTHR shares on Jan. 16 at an average of $460.98 and has sold a total of 200 shares in recent weeks (Dec. 11, Dec. 23, Jan. 5), cutting her holding to 320 shares — a 13.51% decrease.
- The stock trades in the mid‑$400s (opened $468.07) with a 50‑day MA of $487.25 and a 1‑year range of $266.98–$519.99; market cap ≈ $20.15B, P/E ≈ 17.7, and a consensus rating of "Moderate Buy" with an average target of $509.50 (analyst targets up to $645).
- United Therapeutics beat quarterly EPS estimates at $7.16 and showed strong profitability (net margin ~40.7%) while reporting $799.5M revenue (slightly below consensus), and analysts project about 24.48 EPS for the current fiscal year.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) Director Jan Malcolm sold 50 shares of the business's stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $460.98, for a total value of $23,049.00. Following the completion of the transaction, the director owned 320 shares in the company, valued at $147,513.60. This trade represents a 13.51% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Jan Malcolm also recently made the following trade(s):
- On Monday, January 5th, Jan Malcolm sold 50 shares of United Therapeutics stock. The stock was sold at an average price of $495.01, for a total value of $24,750.50.
- On Tuesday, December 23rd, Jan Malcolm sold 50 shares of United Therapeutics stock. The shares were sold at an average price of $512.12, for a total value of $25,606.00.
- On Thursday, December 11th, Jan Malcolm sold 50 shares of United Therapeutics stock. The stock was sold at an average price of $482.98, for a total value of $24,149.00.
United Therapeutics Price Performance
Shares of NASDAQ UTHR opened at $468.07 on Wednesday. The stock has a fifty day moving average price of $487.25 and a 200 day moving average price of $412.06. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $519.99. The company has a market cap of $20.15 billion, a PE ratio of 17.74, a P/E/G ratio of 2.49 and a beta of 0.84.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, topping analysts' consensus estimates of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The company had revenue of $799.50 million during the quarter, compared to the consensus estimate of $812.87 million. During the same quarter in the prior year, the firm earned $6.39 EPS. United Therapeutics's quarterly revenue was up 6.8% on a year-over-year basis. Analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of equities research analysts have weighed in on the company. HC Wainwright lifted their price objective on United Therapeutics from $500.00 to $525.00 and gave the company a "buy" rating in a report on Thursday, October 30th. Morgan Stanley set a $447.00 price target on United Therapeutics in a report on Wednesday, October 29th. Wells Fargo & Company upped their price objective on United Therapeutics from $414.00 to $423.00 and gave the stock an "equal weight" rating in a report on Thursday, October 30th. UBS Group increased their price objective on United Therapeutics from $600.00 to $645.00 and gave the stock a "buy" rating in a research report on Tuesday, January 6th. Finally, Royal Bank Of Canada boosted their target price on shares of United Therapeutics from $569.00 to $587.00 and gave the stock an "outperform" rating in a research report on Thursday, October 30th. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, United Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $509.50.
View Our Latest Report on UTHR
Hedge Funds Weigh In On United Therapeutics
Hedge funds have recently bought and sold shares of the company. Chung Wu Investment Group LLC purchased a new stake in United Therapeutics during the second quarter worth $29,000. WealthCollab LLC raised its stake in shares of United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock worth $30,000 after buying an additional 38 shares during the last quarter. Rakuten Securities Inc. raised its stake in shares of United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock worth $30,000 after buying an additional 46 shares during the last quarter. Wilmington Savings Fund Society FSB boosted its position in shares of United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company's stock worth $37,000 after buying an additional 49 shares in the last quarter. Finally, Abich Financial Wealth Management LLC acquired a new stake in United Therapeutics in the 3rd quarter valued at about $44,000. 94.08% of the stock is owned by hedge funds and other institutional investors.
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
